Data on a potential new treatment for HAE to be presented at the 2025 HAEi Regional Conference EMEA

One poster and one oral presentation on the potential new HAE treatment, navenibart, will be presented by the pharmaceutical company Astria Therapeutics, at the 2025 HAEi Regional Conference EMEA taking in Rome, Italy between 10-12 October 2025.

Dr William Lumry, MD, ARA Research Center, Dallas, United States of America, will share information on the global Phase-3 trial of navenibart in a presentation of a poster titled, “ALPHA-ORBIT – a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with HAE.” The poster will be presented on Friday 10 October 10 at 6:30 pm CEST.

Dr Lumry will also present initial information on the safety and efficacy of navenibart in an oral presentation titled, “Results From The ALPHA-STAR Trial, A Phase-1b/2 Single And Multiple Dose Study To Assess The Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of Navenibart In Participants With Hereditary Angioedema (HAE).” The oral presentation will take place on Saturday 11 October at 9:45 am CEST.

(Source: Astria)